



ASX Announcement

European and Canadian Patent Offices Grant NanoCelle® Patents Offering Protection until 2036.

SYDNEY, June 23, 2021 - Medlab Clinical Ltd (ASX.MDC), an Australian biotech using delivery platforms to enhance medicines, is very pleased to announce both European and Canadian Patent offices have granted patent protection for the NanoCelle® delivery platform until 2036.

Further to the Intention to Grant (EU) ASX announcement 7 April 2021, the full approval in the European Union and at the same time Canada significantly globalises protection of the NanoCelle® technology. In September 2020, Medlab announced Australia as the first jurisdiction to grant protection.

NanoCelle® protection now includes:

Oceania:

- Australia
- New Zealand (Accepted)

Asia:

- Hong Kong (Grant Requested)

Europe:

- Albania
- Austria
- Belgium
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy

- Latvia
- Lithuania
- Luxembourg
- Malta
- Monaco
- Netherlands
- North Macedonia
- Norway
- Poland
- Portugal
- Romania
- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- United Kingdom

America's:

- Canada

Medlab is awaiting a decision from the Singapore and United States Patent Office.

To date all jurisdictions have offered protection until 2036.

NanoCelle® is Medlab's proprietary sub-micron delivery system with a diverse real-world application. Medlab has several in Australian market applications of NanoCelle® in both nutraceuticals and high value drug candidates, such as NanaBis™ for cancer bone pain and NanoCBD™ for anxiety and stress as per the recently announced heads of Agreement with Arrotex.

Laurence McAllister, Medlab Board Director and former ANZ - Managing Director of Sanofi Pharmaceuticals and Board Director of Medicines Australia stated "In Pharmaceutical or Biotech company terms, this is quite an achievement enabled by Medlab's significant financial and focused people resources to realise this highly valued IP protection across 41 Countries through to 2036. Our next well-developed working progress target is the US".

Mr. McAllister also noted that "our intellectual property (IP) protection developments combined with the quality and consistent synthetic approach announcement to address the US\$70B opioid crisis, have step-changed our level of engagements with several global facing Pharma and Biotech potential partnering discussions with regards to NanaBis™ and NanoCelle® following our CEO Dr Sean Hall's presentation at the highly respected Jefferies New York conference on the 2nd of June. To put this into perspective as highlighted at Jefferies with credible 3rd party sources, is that our addressable market for NanoCelle® is US\$260B globally and Medlab is focused to participate in this space with real clinical and approved medicinal differentiation."

As a result of the recent Jefferies Healthcare Conference in New York, Medlab has received another 15 invitations for new partnering discussions. Working with our Investment Relations team in New York, EDISON's, Medlab has secured several new US facing Institutional meetings interested in the Medlab story.

ENDS

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Medlab Clinical Limited.

About Medlab Clinical:

Medlab Clinical LTD (ASX:MDC) is pioneering the development and Commercialisation of a delivery platform, allowing for enhanced medical properties, including increased efficacy, safety, patient compliance and stability. Medlab's pipeline comprises a number of small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies. Patented lead drug candidate NanaBis™ has been developed for cancer bone pain as a viable alternative to opioid use. Data to date, strongly suggests NanaBis™ may be equally effective in non-cancer neuropathic pain. NanoCelle®, the patented delivery platform is wholly owned by Medlab and developed in Medlab's owned OGTR Registered Laboratory. NanoCelle® is designed to address known medication problems, addressing global unmet medical needs. Medlab operates in Australia (Head Office), USA, and the UK. For more information, please visit www.medlab.co

Medlab – *better medicines, better patient care*

Contact:

Medlab Clinical
Dr. Sean Hall, CEO
Sean_hall@medlab.co

Medlab US Investor Relations
Laine Yonker
lyonker@edisongroup.com